Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hong Seok Choi has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Garam Kim

    Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea

    16 shared publications
  • Poshan Yugal Bhattarai

    Honam Regional Future Drug Development Convergence Education & Research Division (BK21 FOUR) College of Pharmacy Chosun University Jeonnam‐Gwangju Special Metropolitan City 61452 Republic of Korea

    10 shared publications
  • Poshan Yugal Bhattarai

    College of Pharmacy, Chosun University, Gwangju, Korea

    10 shared publications
  • Sung-Chul Lim

    Department of Pathology, School of Medicine, Chosun University, Gwangju, Republic of Korea

    6 shared publications
  • Hyo Jeong Yun

    College of Pharmacy, School of Medicine, Chosun University, Gwangju, Republic of Korea

    5 shared publications
  • Prem Khanal

    College of Pharmacy, Chosun University, Gwangju 501-759, South Korea.

    5 shared publications

Latest Publications

  • Open Access

    Glucose and Glutamine Deprivation Promotes Breast Cancer Lung Metastasis via BRD4‐Dependent Enhancer Activation

    by Poshan Yugal Bhattarai, Arathy Vasukutty, Yujin Na, Sung‐Chul Lim, Hong Seok Choi

    Nutrient deprivation in the tumor microenvironment drives metastatic progression. However, its role in breast cancer metastasis and underlying epigenetic mechanisms remain unclear. We identify an enhancer‐driven transcriptional program that promotes breast cancer metastasis under nutrient deprivation. Transient glucose–glutamine deprivation in MCF7 and MDA‐MB‐231 cells induces the expression of genes involved in migration, invasion, and metastasis. Chromatin immunoprecipitation sequencing shows distinct enhancer activation, marked by increased histone H3 lysine 27 and bromodomain‐containing protein 4 (BRD4) recruitment. Targeted enhancer acetylation using dCas9–p300 increases cognate gene expression. Motif and CUT&RUN analyses indicate the enrichment and direct binding of ATF3 and c‐JUN at enhancers—essential for their activation. Transient transcriptome sequencing shows an increase in endothelin 1 ( EDN1 ) enhancer RNA (eRNA) transcription to facilitate enhancer activation, which is reduced by treatment with eRNA‐targeting antisense oligonucleotides (ASOs). In an orthotopic mouse model, BRD4 inhibition using JQ1 or MZ1 suppresses 4T1 cell metastasis. EDN1 enhancer acetylation with dCas9–p300 increases MCF7 tumor growth, which is reduced by BRD4 inhibition or ASO treatment. BRD4 and EDN1 expression is commonly upregulated in human breast metastasis. These findings define nutrient stress‐responsive enhancers as epigenetic drivers of metastatic adaptation and highlight their therapeutic potential in breast cancer.

  • Open Access

    Epitranscriptomic Regulation by m6A in Metabolic Reprogramming and Cellular Plasticity during Cancer Progression

    by Arathy Vasukutty, Poshan Yugal Bhattarai, Hong Seok Choi

    Arathy Vasukutty, Poshan Yugal Bhattarai, Hong Seok Choi. DTT 2025;4:148-56. https://doi.org/10.58502/DTT.25.0015


  • Open Access

    Ebselen Suppresses Breast Cancer Tumorigenesis by Inhibiting YTHDF1-Mediated c-Fos Expression

    by Arathy Vasukutty, Poshan Yugal Bhattarai, Hong Seok Choi

    YTHDF1, an N6-methyladenosine (m6A)-binding protein, plays a key role in breast cancer progression, yet its therapeutic targeting remains underexplored. In this study, we investigated the anticancer effects of the novel YTHDF1 inhibitor ebselen in breast cancer cells. Ebselen treatment reduced cell viability in a dose-dependent manner and induced apoptosis, as demonstrated by Annexin V staining, Sub-G1 accumulation, and DNA fragmentation. Consistently, ebselen increased reactive oxygen species (ROS) production and impaired autophagy induction. Mechanistically, ebselen impaired YTHDF1-mediated stabilization and translation of FOS mRNA, leading to decreased c-Fos expression. In addition, ebselen suppressed anchorage-independent growth in vitro and significantly reduced tumor growth in an orthotopic mouse model. These findings highlight YTHDF1 as a promising therapeutic target and support ebselen as a potential small-molecule inhibitor for breast cancer treatment.


  • Enhancer regulation in cancer: from epigenetics to m6A RNA modification

    by Arathy Vasukutty, Poshan Yugal Bhattarai, Hong Seok Choi

    Enhancers are crucial cis-regulatory DNA elements that regulate gene transcription by interacting with promoters, often over long genomic distances. Unlike promoters, their activity is independent of orientation or proximity to the gene. Active enhancers are transcribed into non-coding enhancer RNAs (eRNAs), which help stabilize enhancer-promoter loops, recruit transcription machinery, and shape the chromatin architecture. These eRNAs are regulated post-transcriptionally, through modifications such as the N6-methyladenosine (m6A) modification, which enhances their stability, facilitates interactions with nuclear reader proteins, and supports transcriptional condensate formation, thereby boosting enhancer activity. Super-enhancers, clusters of strong enhancers marked by high levels of modified H3 histone protein, acetylated at lysine 27, generate abundant eRNAs and are key drivers of gene expression in development and cancer. This review offers a comprehensive overview of the structure and function of enhancers and super-enhancers, highlights their regulatory roles, and examines the emerging contribution of m6A RNA modification in enhancer-mediated transcription during carcinogenesis. Additionally, we discuss experimental approaches for studying enhancer activity and explore potential therapeutic strategies targeting enhancer-associated pathways in cancer. By integrating recent advances in enhancer research, we aim to shed light on the intricate molecular choreography that orchestrates gene expression and its dysregulation in cancer.


  • Open Access

    Regulation of m6A Methylome in Cancer: Mechanisms, Implications, and Therapeutic Strategies

    by Poshan Yugal Bhattarai, Garam Kim, Dibikshya Bhandari, Pratikshya Shrestha, Hong Seok Choi

    Reversible N6-adenosine methylation of mRNA, referred to as m6A modification, has emerged as an important regulator of post-transcriptional RNA processing. Numerous studies have highlighted its crucial role in the pathogenesis of diverse diseases, particularly cancer. Post-translational modifications of m6A-related proteins play a fundamental role in regulating the m6A methylome, thereby influencing the fate of m6A-methylated RNA. A comprehensive understanding of the mechanisms that regulate m6A-related proteins and the factors contributing to the specificity of m6A deposition has the potential to unveil novel therapeutic strategies for cancer treatment. This review provides an in-depth overview of our current knowledge of post-translational modifications of m6A-related proteins, associated signaling pathways, and the mechanisms that drive the specificity of m6A modifications. Additionally, we explored the role of m6A-dependent mechanisms in the progression of various human cancers. Together, this review summarizes the mechanisms underlying the regulation of the m6A methylome to provide insight into its potential as a novel therapeutic strategy for the treatment of cancer.


  • The PIN1-YTHDF1 axis promotes breast tumorigenesis via the m6A-dependent stabilization of AURKA mRNA

    by Pratikshya Shrestha, Garam Kim, Hyelim Kang, Poshan Yugal Bhattarai, Hong Seok Choi

    The post-transcriptional processing of N6-methyladenosine (m6A)-modified mRNA by YTH domain-containing family protein 1 (YTHDF1) plays a crucial role in the regulation of gene expression. Although YTHDF1 expression is frequently upregulated in breast cancer, the regulatory mechanisms for this remain unclear. In this study, we examined the role of peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) in regulating YTHDF1 stability in breast cancer cells. The WW domain of PIN1 interacted with YTHDF1 in a phosphorylation-dependent manner. Additionally, PIN1 overexpression increased YTHDF1 stability by preventing ubiquitin-dependent proteasomal degradation. Furthermore, using the MS2-tagged RNA pull-down assay, we identified Aurora kinase A (AURKA) mRNA as a bona fide substrate of YTHDF1. PIN1-mediated YTHDF1 stabilization increased the stability of AURKA mRNA in an m6A-dependent manner. Furthermore, YTHDF1 knockout reduced AURKA protein expression levels, resulting in anticancer effects in breast cancer cells, including decreased cell proliferation, cell cycle arrest at the G0/G1 phase, apoptotic cell death, and decreased spheroid formation. The anticancer effects induced by YTHDF1 knockout were reversed by AURKA overexpression. Similarly, the knockout of PIN1 produced comparable anticancer effects to those observed in YTHDF1-knockout cells, and these effects were reversed upon overexpression of YTHDF1. In conclusion, the findings of our study suggest that increased YTHDF1 stability induced by PIN1 promotes breast tumorigenesis via the stabilization of AURKA mRNA. Targeting the PIN1/YTHDF1 axis may represent a novel therapeutic strategy for breast cancer.


  • Sirtuin 5-mediated deacetylation of TAZ at K54 promotes melanoma development

    by Garam Kim, Poshan Yugal Bhattarai, Sung-Chul Lim, Kwang Youl Lee, Hong Seok Choi

    Purpose Nuclear accumulation of YAP/TAZ promotes tumorigenesis in several cancers, including melanoma. Although the mechanisms underlying the nuclear retention of YAP are known, those underlying the retention of TAZ remain unclear. Our study investigates a novel acetylation/deacetylation switch in TAZ, governing its subcellular localization in melanoma tumorigenesis. Methods Immunoprecipitation/Western blot assessed TAZ protein interactions and acetylation. SIRT5 activity was quantified with enzyme-linked immunosorbent assay. Immunofluorescence indicated TAZ nuclear localization. TEAD transcriptional activity was measured through luciferase reporter assays. ChIP detected TAZ binding to the CTGF promoter. Transwell and wound healing assays quantified melanoma cell invasiveness and migration. Metastasis was evaluated using a mouse model via tail vein injections. Clinical relevance was explored via immunohistochemical staining of patient tumors. Results CBP facilitated TAZ acetylation at K54 in response to epidermal growth factor stimulation, while SIRT5 mediated deacetylation. Acetylation correlated with phosphorylation, regulating TAZ’s binding with LATS2 or TEAD. TAZ K54 acetylation enhanced its S89 phosphorylation, promoting cytosolic retention via LATS2 interaction. SIRT5-mediated deacetylation enhanced TAZ-TEAD interaction and nuclear retention. Chromatin IP showed SIRT5-deacetylated TAZ recruited to CTGF promoter, boosting transcriptional activity. In a mouse model, SIRT5 overexpression induced melanoma metastasis to lung tissue following the injection of B16F10 melanocytes via the tail vein, and this effect was prevented by verteporfin treatment. Conclusions Our study revealed a novel mechanism of TAZ nuclear retention regulated by SIRT5-mediated K54 deacetylation and demonstrated the significance of TAZ deacetylation in CTGF expression. This study highlights the potential implications of the SIRT5/TAZ axis for treating metastatic melanoma.


  • Open Access

    STM2457 Inhibits Breast Cancer Tumorigenesis via the Inhibition of METTL3

    by Pratikshya Shrestha, Hyelim Kang, Ah-Yeong Song, Sun-Young Jo, Poshan Yugal Bhattarai, Hong Seok Choi

    Pratikshya Shrestha, Hyelim Kang, Ah-yeong Song, Sun-young Jo, Poshan Yugal Bhattarai, Hong Seok Choi. DTT 2023;2:80-7. https://doi.org/10.58502/DTT.23.0015


  • METTL3 stabilization by PIN1 promotes breast tumorigenesis via enhanced m6A-dependent translation

    by Poshan Yugal Bhattarai, Garam Kim, Sung-Chul Lim, Ramesh Mariappan, Takbum Ohn, Hong Seok Choi

    Methyltransferase-like 3 (METTL3) is the catalytic subunit of the N6-adenosine methyltransferase complex responsible for N6-methyladenosine (m6A) modification of mRNA in mammalian cells. Although METTL3 expression is increased in several cancers, the regulatory mechanisms are unclear. We explored the regulatory roles of peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) in METTL3 stability and m6A modification of mRNA. PIN1 interacted with METTL3 and prevented its ubiquitin-dependent proteasomal and lysosomal degradation. It stabilized METTL3, which increased the m6A modification of transcriptional coactivator with PDZ-binding motif (TAZ) and epidermal growth factor receptor (EGFR) mRNA, resulting in their efficient translation. PIN1 knockout altered the distribution of TAZ and EGFR mRNA from polysomes into monosomes. Inhibition of MEK1/2 kinases and PIN1 destabilized METTL3, which impeded breast cancer cell proliferation and induced cell cycle arrest at the G0/G1 phases. METTL3 knockout reduced PIN1 overexpression-induced colony formation in MCF7 cells and enhanced tumor growth in 4T1 cells in an orthotopic mouse model. In clinical settings, METTL3 expression significantly increased with tumor progression and was positively correlated with PIN1 expression in breast cancer tissues. Thus, PIN1 plays a regulatory role in mRNA translation, and the PIN1/METTL3 axis may be an alternative therapeutic target in breast cancer.